secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-08-11T20:45:16+00:00
Accession:  0001193125-26-344878
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics Q2 2026: cash $494.9M, net loss $44.7M; pipeline milestones on track
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $494.9M at 6/30/26 vs $360.0M at 12/31/25; runway into 2029.
- Q2 2026 net loss $44.7M ($0.76/share) vs $33.7M ($0.77/share) in Q2 2025; H1 loss $68.9M ($1.22/share).
- R&D expenses Q2 $34.9M (vs $28.1M); G&A $13.1M (vs $8.4M); both up on clinical progress and personnel costs.
- Recognized $20M H1 2026 license revenue from Shionogi milestone for MZE001 (Pompe disease).
- MZE829 HORIZON updated data late 2026/early 2027 (3 cohorts); pivotal trial H1 2027. MZE782 PKU topline 2027; CKD trial H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/0001193125-26-344878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526344878/maze-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer